Abbott to pay over $384 million in settlement over federal claims tied to Sturgis facility

Abbott Laboratories will pay $385 million to resolve claims related to a 2022 baby formula recall and shortage, though the company denies any fault or liability. The recall affected brands like Similac and exacerbated supply issues during the COVID-19 pandemic.

Abbott Laboratories will pay $385M to settle claims related to contamination at its Sturgis, Michigan baby formula plant, which led to 2022 supply shortages. The settlement resolves DOJ and state lawsuits, but Abbott denies liability. The plant was closed and later reopened. The recall affected brands like Similac, exacerbating supply chain issues.

Abbott Labs will pay $385M to settle legal claims related to a 2022 contamination inquiry at its Sturgis, Michigan plant, which caused a recall and supply shortages. The settlement does not admit fault. Abbott maintains no unopened formula tested positive for Cronobacter. The plant reopened in June 2022 after a closure. The Biden administration took steps to alleviate the shortage.

Abbott Laboratories agreed to pay $385M to settle allegations of quality and safety issues in its infant formula and nutritional products, according to a complaint filed by whistleblowers represented by Stein Mitchell Beato & Missner LLP. The settlement resolves False Claims Act allegations related to products manufactured at Abbott's Sturgis, Michigan, and Casa Grande, Arizona, plants between 2018 and 2022. The whistleblowers will receive $69M from the settlement.

Abbott Laboratories will pay $385 million to settle claims related to contamination at its Michigan baby formula plant, which caused supply shortages in 2022. The recall affected brands like Similac. Separately, Amazon suspended its partnership with cargo airline 21 Air following a fatal crash in Miami.

Abbott Laboratories will pay $385 million to resolve claims related to contamination at its Michigan infant formula plant, including a 2022 recall. The settlement does not admit fault. The plant's closure contributed to a nationwide formula shortage. The DOJ's criminal investigation has closed. Abbott's Similac brand was among those recalled.